SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending after reporting strong Q4 earnings that surpassed estimates, yet its Q1 revenue guidance, perceived as softer than elevated AI expectations, triggered a 'sell the news' reaction. The community is actively debating if the market's swift correction is an overreaction to otherwise robust long-term data center growth projections and confirmed product timelines.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending higher after its Q2 earnings surpassed revenue and EPS estimates and substantially raised its future revenue guidance, igniting community discussions around its massive growth, strategic margin compression, and high short interest potentially leading to a squeeze.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing a significant sell-off after unexpected 2026 guidance projected declining sales, fueling widespread community frustration with management's pessimistic tone. Investors are actively debating the impact of fierce GLP-1 competition and US pricing pressures, despite promising early demand for its oral weight-loss pill.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending after its Q4 earnings report presented a mixed picture, showing strong revenue growth and record free cash flow but missing adjusted EPS estimates and providing a slightly softer Q1 outlook. The community is actively debating whether the company's robust platform growth and long-term autonomous vehicle strategy as an aggregator can overcome immediate profit concerns and increasing competition.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending due to a recent short-seller report alleging financial crimes, which the company has strongly refuted. This has sparked community debate about market manipulation versus a buying opportunity, especially with a new analyst upgrade and positive sector signals ahead of its anticipated earnings.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending due to a strong Q4 earnings beat and an optimistic 2026 outlook, fueled by explosive demand for its GLP-1 drugs Mounjaro and Zepbound, which further establishes its market leadership over rivals, despite community discussions around its high valuation and calls for a stock split.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending due to widespread community discussion and FUD surrounding unverified claims from "Epstein files" linking Jeffrey Epstein to its creation, with bears amplifying concerns for further downside, while bulls dismiss it as manufactured FUD and a significant long-term buying opportunity.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is trending after reporting strong earnings and an optimistic outlook, prompting multiple analyst upgrades and widespread community discussion about a potential solar sector recovery and a short squeeze, bolstered by new product introductions.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amidst a significant sell-off, heavily influenced by the broader cryptocurrency market downturn, which impacts its substantial digital asset revenue. The community is sharply divided ahead of upcoming earnings, with some expressing deep concern over its valuation and crypto exposure, while others view the current dip as a compelling buying opportunity given Robinhood's diversification into new financial services.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is a major talking point ahead of its upcoming earnings, with fervent speculation around a new hyperscaler data center contract following its significant Microsoft deal, though the community is divided on price action should a deal not materialize as expected.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Crescent Biopharma (NASDAQ:CBIO) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Crescent Biopharma from a "hold" rating to a "sell" rating in a report on Saturday...

Crescent Biopharma (NASDAQ:CBIO) Upgraded by Guggenheim to Strong-Buy Rating

Guggenheim upgraded Crescent Biopharma to a "strong-buy" rating and set a $35.00 price objective for the company in a research note on Wednesday...

Crescent Biopharma (NASDAQ:CBIO) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened

Crescent Biopharma (NASDAQ:CBIO) Share Price Crosses Above 200 Day Moving Average - Here's Why...

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Brokerages

Shares of Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) have been given a consensus recommendation of "Buy" by the seven brokerages that are currently covering the company, MarketBeat.com...

Braidwell LP Invests $4.22 Million in Crescent Biopharma, Inc. $CBIO

Braidwell LP acquired a new stake in Crescent Biopharma, Inc. (NASDAQ:CBIO - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange...

BVF Inc. IL Makes New Investment in Crescent Biopharma, Inc. $CBIO

BVF Inc. IL purchased a new stake in Crescent Biopharma, Inc. (NASDAQ:CBIO - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and...

Fairmount Funds Management Llc Purchases 1,360,000 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock

Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) Director Fairmount Funds Management Llc bought 1,360,000 shares of the stock in a transaction on Thursday, December 4th. The shares were...

Crescent Biopharma (NASDAQ:CBIO) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded shares of Crescent Biopharma from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Crescent Biopharma is partnering with the Chinese firm Kelun-Biotech to expand its oncology drug pipeline and accelerate its combination strategy.&nbsp;</li><li>The company also announced a $185 million private placement, expected to close around December 8.</li><li>Stocktwits retail sentiment for the stock was ‘extremely bullish’.</li></ul><a href="https://stocktwits.com/symbol/CBIO">Crescent Biopharma (CBIO)</a> announced a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co. to expand its pipeline of oncology drugs and speed up its combination strategy. The company also announced a $185 million private placement, expected to close around December 8.Shares of Crescent were up over 40% in pre-market trading.The company said it has three distinct programs that are expected to enter the clinic in 2026. In addition, the private financing will boost its cash runway.“We’re excited to share the tremendous progress we’ve made executing on our strategy of building a robust portfolio of next-generation oncology therapeutics," said Joshua Brumm, chief executive officer of Crescent.<h2 class="st-heading-2">Partnership Details</h2>The deal will allow Crescent exclusive rights to research, develop, and commercialize SKB105 (also known as CR-003) in the United States, Europe, and all markets excluding Greater China. This is an integrin beta-6 (ITGB6)-directed antibody-drug conjugate (ADC) with a topoisomerase payload.Meanwhile, Kelun-Biotech will obtain exclusive rights to research, develop, and commercialize CR-001 in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. The drug is Crescent’s bispecific antibody that the company says has the potential to be foundational in immuno-oncology.Both Crescent and Kelun-Biotech will retain the right to independently develop CR-001 in combination with proprietary ADC pipeline assets.“CR-001, our PD-1 x VEGF bispecific antibody, has the potential to be a foundational immuno-oncology backbone and the partnership we announced with Kelun-Biotech today has enhanced our pipeline of ADCs and accelerated our efforts to deliver potentially best-in-class novel combination therapies,” said Brumm.<h2 class="st-heading-2">Retail Reaction</h2>Stocktwits retail sentiment for the stock changed from ‘neutral’ to ‘extremely bullish’ while message volume jumped to ‘extremely high’.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_5_01_28_PM_png_71929a932d.webp" alt="Stocktwits retail sentiment for the stock is ‘extremely bullish’ while message volume remained ‘extremely high’."> One user noted they were ‘bullish’ on the stock, adding “In with a starter!”<stembedurl>https://stocktwits.com/KuruHabesha/message/638133096</stembedurl>Another said that the stock was long forgotten in their portfolio.<stembedurl>https://stocktwits.com/walkingprinter/message/638132752</stembedurl>Shares of Crescent Biopharma were down about 47% year-to-date but have gained almost 8% in the last month.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/why-tigr-stock-rose-premarket-trade-today/cLILDuARESm">Here’s Why TIGR Stock Rose In Premarket Today – And Retail Traders Think The Rally’s Just Starting</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Researcher performing microbiology separator for PCR diagnosis test in pathology laboratory. 

The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today

Crescent Biopharma announced a strategic partnership with the Chinese firm Sichuan Kelun-Biotech Biopharmaceutical Co. to fast-track its global oncology pipeline. 

Equity

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Analysts

Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) has been given a consensus recommendation of "Buy" by the seven ratings firms that are currently covering the firm, Marketbeat.com reports...

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Crescent Biopharma Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $GOOGL earnings on Wednesday?

CBIO
Crescent Biopharma Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CBIO News

CBIOCrescent Biopharma Inc.